Larimar Therapeutics, Inc. (LRMR)
NASDAQ: LRMR · Real-Time Price · USD
6.08
-0.30 (-4.70%)
At close: Nov 20, 2024, 4:00 PM
5.96
-0.12 (-2.04%)
After-hours: Nov 20, 2024, 5:50 PM EST
Larimar Therapeutics Employees
Larimar Therapeutics had 42 employees as of December 31, 2023. The number of employees increased by 16 or 61.54% compared to the previous year.
Employees
42
Change (1Y)
16
Growth (1Y)
61.54%
Revenue / Employee
n/a
Profits / Employee
-$1,542,214
Market Cap
387.94M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 42 | 16 | 61.54% |
Dec 31, 2022 | 26 | -5 | -16.13% |
Dec 31, 2021 | 31 | 3 | 10.71% |
Dec 31, 2020 | 28 | 12 | 75.00% |
Dec 31, 2019 | 16 | - | - |
Related Stocks
Company Name | Employees |
---|---|
Sonida Senior Living | 3,955 |
Canopy Growth | 1,029 |
Sangamo Therapeutics | 405 |
Akebia Therapeutics | 167 |
KalVista Pharmaceuticals | 150 |
Rigel Pharmaceuticals | 147 |
4D Molecular Therapeutics | 147 |
Tango Therapeutics | 140 |
LRMR News
- 22 days ago - Larimar Therapeutics Reports Third Quarter 2024 Operating and Financial Results - GlobeNewsWire
- 5 weeks ago - Larimar Therapeutics' New Drug Could Transform Treatment For Rare Neurological Disease, Analyst Sees Over 200% Upside For Stock - Benzinga
- 6 weeks ago - Larimar Therapeutics' Friedreich's Ataxia Approach Could Have Considerable Upside Potential - Seeking Alpha
- 2 months ago - Larimar Therapeutics Announces Three Poster Presentations at the Upcoming International Congress for Ataxia Research - GlobeNewsWire
- 6 months ago - Larimar: Stronger Buy Now More Than Ever After Partial Clinical Hold Completely Removed - Seeking Alpha
- 6 months ago - Larimar Therapeutics Selected by FDA to Participate in START Pilot Program for Nomlabofusp in Friedreich's Ataxia - GlobeNewsWire
- 6 months ago - Larimar Therapeutics Announces FDA has Removed Partial Clinical Hold for Nomlabofusp Program in Friedreich's Ataxia - GlobeNewsWire
- 7 months ago - Larimar Therapeutics Reports First Quarter 2024 Operating and Financial Results - GlobeNewsWire